journal article·2025-09

Controlled Delivery of C-C Motif Chemokine Ligand 25 by a Hydrogel for Tumor Microenvironment Remodeling in Triple Negative Breast Cancer

Meng Guan, Junfeng Ding, Ge Zhu, Kuirong Mao, Xiandi Meng, Xiuxiu Cong, Huizhu Tan, Yanbao Xin, Mengfei Zhao, Jiaxuan Li, Haorui Wang, Yue Lv, Huating Sun, Chaoliang He, Hongmei Chen, Yong-Guang Yang, Yanqiu Song, Yuning Zhang, Tianmeng Sun

Acta Biomaterialia· Volume 203
Publisher page

Abstract

Triple-negative breast cancer (TNBC), characterized by its heterogeneity and poor clinical prognosis, presents substantial unmet medical needs. Although exciting progress has been made in immunotherapy for TNBC, optimizing the composition of immune cells within the tumor microenvironment (TME) remains a critical challenge. In this study, we demonstrate that CCL25-transduced tumor cells significantly enhance the accumulation of CCR9+CD8+T cells within tumors, translating into inhibited TNBC tumor growth in vivo. To further exploit this mechanism, we developed an injectable, thermo-responsive hydrogel loaded with CCL25 for intratumoral delivery, aimed at recruiting CCR9+ cells into the TME. Our results revealed that the influence of CCL25 on the TME is both dose- and time-dependent, mediated through the precise regulation of CCR9+ cells infiltration into tumor tissues. Furthermore, CCL25-loaded hydrogel, when administered at an appropriate dose and timing, could enhance the therapeutic response to PD-1 inhibitors, credited to the activation of a T cell-dependent antitumor immunity. This innovative approach not only provides deeper insights into the role of the chemokine system in tumor biology but also suggests a promising strategy for enhancing the efficacy of TNBC immunotherapy. The potential of hydrogel-based chemokine delivery systems to remodel the TME could have significant implications for future cancer treatment. STATEMENT OF SIGNIFICANCE: In our study, we developed a thermo-responsive injectable hydrogel for intratumoral delivery of CCL25. Our findings demonstrate that CCL25@gel promotes the infiltration of CCR9+CD8+T cells into the tumor microenvironment in a dose- and time-dependent manner. Notably, at an optimal dose and administration schedule, CCL25@gel significantly enhances the therapeutic response to PD-1 inhibitors, thereby improving the efficacy of immunotherapy in triple-negative breast cancer (TNBC). These results highlight the potential of CCL25 in modulating the immune landscape of the tumor microenvironment and emphasize the importance of optimizing key delivery parameters-dose, timing, and frequency-to maximize therapeutic benefits. Moreover, this work provides valuable insights into chemokine-based immunotherapy for TNBC, offering new avenues for more effective treatment strategies.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Chemokine receptors and signaling · Angiogenesis and VEGF in Cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (59)

Show source-provided references
1. Breast cancer treatment10.1001/jama.2018.19323 ↗
2. Treatment landscape of triple-negative breast cancer — Expanded options, evolving needs10.1038/s41571-021-00565-2 ↗
3. Advances in immunotherapy for triple-negative breast cancer10.1186/s12943-023-01850-7 ↗
4. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers10.1200/JCO.18.01010 ↗
5. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers10.1172/JCI96313 ↗
6. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer10.1038/s41523-021-00219-7 ↗
7. Tumor-infiltrating lymphocytes in breast cancer and implications for clinical practice10.1016/j.bbcan.2017.10.003 ↗
8. Intratumoral CD8(+) T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer10.1016/j.ccell.2023.01.004 ↗
9. CD8 T cell score as a prognostic biomarker for triple negative breast cancer10.3390/ijms21186968 ↗
10. How chemokines organize the tumour microenvironment10.1038/s41568-023-00635-w ↗
11. Role of chemokine systems in cancer and inflammatory diseases10.1002/mco2.147 ↗
12. The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double- and single-positive thymocytes expressing the TECK receptor CCR910.1002/1521-4141(200001)30:1<262::AID-IMMU262>3.0.CO;2-0 ↗
13. The role of Thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the Mucosal immune system10.4049/jimmunol.165.9.5069 ↗
14. A role for CCR9 in T lymphocyte development and migration10.4049/jimmunol.168.6.2811 ↗
15. Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity10.1016/j.jaut.2016.01.001 ↗
16. A subset of CCL25-induced gut-homing T cells affects intestinal immunity to infection and cancer10.3389/fimmu.2019.00271 ↗
17. Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9(+) T cells10.1126/sciadv.aax4690 ↗
18. Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies10.1038/icb.2015.15 ↗
19. Advances and trends of hydrogel therapy platform in localized tumor treatment: a review10.1002/jbm.a.37062 ↗
20. Hydrogel systems for targeted cancer therapy
21. Peptide-hydrogel nanocomposites for anti-cancer drug delivery10.3390/gels9120953 ↗
22. Localized chemotherapy based on injectable hydrogel boosts the antitumor activity of adoptively transferred T lymphocytes In vivo
23. Injectable polypeptide hydrogel depots containing dual immune checkpoint inhibitors and doxorubicin for improved tumor immunotherapy and post-surgical tumor treatment10.3390/pharmaceutics15020428 ↗
24. Design of an injectable polypeptide hydrogel depot containing the immune checkpoint blocker anti-PD-L1 and doxorubicin to enhance antitumor combination therapy10.1002/mabi.202100049 ↗
25. Enhanced antitumor chemo-immunotherapy by local co-delivery of chemotherapeutics, immune checkpoint blocking antibody and IDO inhibitor using an injectable polypeptide hydrogel10.1002/pol.20210955 ↗
26. Interleukin-15 and cisplatin co-encapsulated thermosensitive polypeptide hydrogels for combined immuno-chemotherapy10.1016/j.jconrel.2017.04.011 ↗
27. DOX/IL-2/IFN-γ co-loaded thermo-sensitive polypeptide hydrogel for efficient melanoma treatment
28. Thermo-induced physically crosslinked polypeptide-based block copolymer hydrogels for biomedical applications10.1093/rb/rbad039 ↗
29. Current landscape of gene-editing technology in biomedicine: applications, advantages, challenges, and perspectives10.1002/mco2.155 ↗
30. Gene editing to enhance the efficacy of cancer cell therapies10.1016/j.ymthe.2021.10.001 ↗
31. Bioengineered nanogels for cancer immunotherapy10.1039/D2CS00247G ↗
32. Designing hydrogels for controlled drug delivery10.1038/natrevmats.2016.71 ↗
33. Hydrogels for mucosal drug delivery10.1021/acsabm.3c00050 ↗
34. Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ10.1038/s43018-020-0036-4 ↗
35. Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment10.1038/s43018-020-0038-2 ↗
36. Platelet-armored nanoplatform to harmonize janus-faced IFN-gamma against tumor recurrence and metastasis10.1016/j.jconrel.2021.08.020 ↗
37. Reassessing granzyme B: unveiling perforin-independent versatility in immune responses and therapeutic potentials10.3389/fimmu.2024.1392535 ↗
38. Imaging and monitoring of granzyme B in the immune response10.1002/wnan.1928 ↗
39. Emerging treatment approaches for triple-negative breast cancer10.1007/s12032-023-02257-6 ↗
40. Emerging therapeutics for patients with triple-negative breast cancer10.1007/s11912-021-01038-6 ↗
41. Immune checkpoint inhibitors for triple-negative breast cancer: from immunological mechanisms to clinical evidence10.1016/j.intimp.2021.107876 ↗
42. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition10.1016/j.annonc.2021.07.007 ↗
43. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC)10.1016/S0960-9776(19)31122-1 ↗
44. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy10.1093/annonc/mdz395 ↗
45. Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes10.1200/JCO.21.02170 ↗
46. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy10.1038/nri.2017.49 ↗
47. Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy10.1038/s41467-023-37656-w ↗
48. Co-infusion of CAR T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumor efficacy in mice10.1016/j.canlet.2023.216287 ↗
49. Chemokine receptor antagonists: role in oncology10.1007/s11912-021-01117-8 ↗
50. Promoting the recruitment, engagement, and reinvigoration of effector T cells via an injectable hydrogel with a supramolecular binding capability for cancer immunotherapy10.1002/adma.202309667 ↗
51. Chemokine 25–induced signaling suppresses colon cancer invasion and metastasis10.1172/JCI62110 ↗
52. The role of chemokine receptor 9/chemokine ligand 25 signaling: from immune cells to cancer cells (Review)
53. Stimuli-responsive hydrogels for protein delivery10.3390/gels9100802 ↗
54. Polymeric DNA hydrogels and their applications in drug delivery for cancer therapy10.3390/gels9030239 ↗
55. Hydrogels for RNA delivery10.1038/s41563-023-01472-w ↗
56. Clinical relevance of tumour-associated macrophages10.1038/s41571-022-00620-6 ↗
57. Tumour-associated macrophages: versatile players in the tumour microenvironment10.3389/fcell.2023.1261749 ↗
58. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial10.1038/s41591-019-0432-4 ↗
59. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study10.1007/s10549-017-4537-5 ↗